Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Corindus Vascular Robotics (NYSEMKT:CVRS) remained flat at $1.17 during midday trading on Wednesday. 78,773 shares of the stock traded hands. The company’s 50 day moving average price is $1.30 and its 200-day moving average price is $1.24. The stock’s market cap is $139.16 million. Corindus Vascular Robotics has a 52-week low of $0.73 and a 52-week high of $3.79.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/corindus-vascular-robotics-inc-cvrs-lifted-to-hold-at-zacks-investment-research-2.html

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts anticipate that Corindus Vascular Robotics will post ($0.25) EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. boosted its stake in shares of Corindus Vascular Robotics by 236.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,000 shares of the company’s stock worth $121,000 after buying an additional 59,000 shares during the period. State Street Corp boosted its stake in Corindus Vascular Robotics by 12.3% in the second quarter. State Street Corp now owns 258,877 shares of the company’s stock worth $369,000 after buying an additional 28,377 shares during the period. GAM Holding AG boosted its stake in Corindus Vascular Robotics by 5.7% in the second quarter. GAM Holding AG now owns 1,060,920 shares of the company’s stock worth $1,522,000 after buying an additional 57,239 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in Corindus Vascular Robotics by 69.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 350,812 shares of the company’s stock worth $502,000 after buying an additional 143,544 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in Corindus Vascular Robotics by 131.6% in the second quarter. BlackRock Fund Advisors now owns 1,353,007 shares of the company’s stock worth $1,935,000 after buying an additional 768,738 shares during the period.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Receive News & Ratings for Corindus Vascular Robotics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.